India Issues Standard Treatment Guidelines for Skin Disorders Across Four AYUSH Systems

Skin disorders can range from mild irritation to chronic inflammatory disease, infections, autoimmune conditions, and malignancies. Because different conditions can produce similar symptoms, accurate diagnosis is essential for selecting appropriate treatment and avoiding complications. On 13 October 2026, India's Ministry of AYUSH announced standard treatment guidelines for managing dermatological disorders across Ayurveda, Siddha, Unani, and Homoeopathy, with the inclusion of Yoga. The guidelines were developed through the AYUSH Vertical of the Directorate General of Health Services, under the Ministry of Health and Family Welfare. The initiative aims to improve standardization, quality assurance, and evidence-informed clinical practice. The guidelines set out recommendations for prevention, diagnosis, treatment, follow-up, and rehabilitation for common skin conditions, including psoriasis, dermatitis, vitiligo, urticaria, and dermatophytosis. Standard treatment guidance can help practitioners document clinical findings consistently, identify patients who require specialist referral, and follow defined approaches to monitoring treatment response. The need for accurate diagnosis is especially important in persistent or worsening skin disease. For example, untreated fungal infections can spread, while certain inflammatory disorders may require long-term management. Suspicious skin lesions may need specialist examination or biopsy to exclude cancer. Traditional medicines can have biologically active ingredients and may cause adverse effects or interact with prescribed drugs. Herbal preparations can also vary in composition, and some products may be contaminated or contain undeclared substances. Therefore, standardized guidelines should be evaluated alongside the evidence supporting individual treatments. Clinical effectiveness and safety cannot be assumed solely because a therapy belongs to a traditional medical system or appears in a guideline document. Medical significance: The announcement represents a healthcare-standardization development in India. Its potential benefit will depend on implementation, practitioner training, patient monitoring, and the strength of evidence supporting individual recommendations. Patients should not delay necessary medical evaluation for serious or persistent skin conditions.